C Scheid
University of Cologne
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by C Scheid.
Journal of Clinical Oncology | 2004
Michael Kiehl; Ludwig Kraut; Rainer Schwerdtfeger; Bernd Hertenstein; Mats Remberger; Nicolaus Kroeger; Mathias Stelljes; Martin Bornhaeuser; Harts Martin; C Scheid; Arnold Ganser; Axel R. Zander; Joachim Kienast; Gerhard Ehninger; Dieter Hoelzer; Volker Diehl; Axel A. Fauser; Olle Ringdén
PURPOSEnThe role of unrelated allogeneic stem-cell transplantation in acute lymphoblastic leukemia (ALL) patients is still not clear, and only limited data are available from the literature. We analyzed factors affecting clinical outcome of ALL patients receiving a related or unrelated stem-cell graft from matched donors.nnnPATIENTS AND METHODSnThe total study population was 264 adult patients receiving a myeloablative allogeneic stem-cell transplant for ALL at nine bone marrow transplantation centers between 1990 and 2002. Of these, 221 patients receiving a matched related or unrelated graft were analyzed. One hundred forty-eight patients received transplantation in complete remission; 62 patients were in relapse; and 11 patients were refractory to chemotherapy before transplant. Fifty percent of patients received bone marrow, and 50% received peripheral blood stem cell from a human leukocyte antigen-identical related (n = 103), or matched unrelated (n = 118) donor.nnnRESULTSnDisease-free survival (DFS) at 5 years was 28%, with 76 patients (34%) still alive (2.2 to 103 months post-transplantation), and 145 deceased (65 relapses, transplant-related mortality, 45%). We observed an advantage regarding DFS in favor of patients receiving transplantation during their first complete remission (CR) in comparison with patients receiving transplantation in or after second CR (P =.014) or who relapsed (P <.001). We observed a clear trend toward improved survival in favor of B-lineage ALL patients compared with T-lineage ALL patients (P =.052), and Philadelphia chromosome-positive patients had no poorer outcome than Philadelphia chromosome-negative patients. Total-body irradiation-based conditioning improved DFS in comparison with busulfan (P =.041).nnnCONCLUSIONnMyeloablative matched related or matched unrelated allogeneic hematopoietic stem-cell transplantation in ALL patients should be performed in first CR.
Leukemia | 2015
Robert Zeiser; Andreas Burchert; Claudia Lengerke; Mareike Verbeek; K. Maas-Bauer; Stephan Metzelder; Silvia Spoerl; Markus Ditschkowski; M. Ecsedi; K. Sockel; Francis Ayuk; S. Ajib; F. S. De Fontbrune; Il-Kang Na; L. Penter; Udo Holtick; Dominik Wolf; E. Schuler; Everett Meyer; Petya Apostolova; Hartmut Bertz; Reinhard Marks; Michael Lübbert; Ralph Wäsch; C Scheid; Friedrich Stölzel; Rainer Ordemann; Gesine Bug; Guido Kobbe; Robert S. Negrin
Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy for SR-GVHD. Patients were classified as having SR-aGVHD (n=54, all grades III or IV) or SR-cGVHD (n=41, all moderate or severe). The median number of previous GVHD-therapies was 3 for both SR-aGVHD (1–7) and SR-cGVHD (1–10). The overall response rate was 81.5% (44/54) in SR-aGVHD including 25 complete responses (46.3%), while for SR-cGVHD the ORR was 85.4% (35/41). Of those patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% (3/44) and 5.7% (2/35) for SR-aGVHD and SR-cGVHD, respectively. The 6-month-survival was 79% (67.3–90.7%, 95% confidence interval (CI)) and 97.4% (92.3–100%, 95% CI) for SR-aGVHD and SR-cGVHD, respectively. Cytopenia and cytomegalovirus-reactivation were observed during ruxolitinib treatment in both SR-aGVHD (30/54, 55.6% and 18/54, 33.3%) and SR-cGVHD (7/41, 17.1% and 6/41, 14.6%) patients. Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Haematologica | 2008
H M Lokhorst; Ingo G. H. Schmidt-Wolf; Pieter Sonneveld; B. van der Holt; Harry Martin; Rmy Barge; Uta Bertsch; Jana Schlenzka; G. Bos; Sandra Croockewit; Sonja Zweegman; Iris Breitkreutz; Peter Joosten; C Scheid; M. van Marwijk-Kooy; Hans-Juergen Salwender; M. H. J. Van Oers; Ron Schaafsma; R Naumann; Harm Sinnige; Igor W. Blau; M Delforge; O. de Weerdt; P. Wijermans; S. Wittebol; U. Duersen; Edo Vellenga; H. Goldschmidt
Thalidomide as part of initial treatment of multiple myeloma improves pre- and post-transplant response by increasing the proportion of patients achieving a very good partial response. In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m2 response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3–4 adverse events were similar in both arms.
Journal of Clinical Oncology | 2014
Matthias Stelljes; Utz Krug; Dietrich W. Beelen; Jan Braess; Maria Cristina Sauerland; Achim Heinecke; Sandra Ligges; Tim Sauer; Petra Tschanter; Gabriela B. Thoennissen; Björna Berning; Hans Jochem Kolb; Albrecht Reichle; Ernst Holler; Rainer Schwerdtfeger; Renate Arnold; C Scheid; Carsten Müller-Tidow; Bernhard J. Woermann; Wolfgang Hiddemann; Wolfgang E. Berdel; Thomas Büchner
PURPOSEnThe majority of patients with acute myeloid leukemia (AML) who achieve complete remission (CR) relapse with conventional postremission chemotherapy. Allogeneic stem-cell transplantation (alloSCT) might improve survival at the expense of increased toxicity. It remains unknown for which patients alloSCT is preferable.nnnPATIENTS AND METHODSnWe compared the outcome of 185 matched pairs of a large multicenter clinical trial (AMLCG99). Patients younger than 60 years who underwent alloSCT in first remission (CR1) were matched to patients who received conventional postremission therapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time in first CR.nnnRESULTSnIn the overall pairwise compared AML population, the projected 7-year overall survival (OS) rate was 58% for the alloSCT and 46% for the conventional postremission treatment group (P = .037; log-rank test). Relapse-free survival (RFS) was 52% in the alloSCT group compared with 33% in the control group (P < .001). OS was significantly better for alloSCT in patient subgroups with nonfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, postremission therapy was an independent factor for OS (hazard ratio, 0.66; 95% CI, 0.49 to 0.89 for alloSCT v conventional chemotherapy), among age, cytogenetics, and bone marrow blasts after the first induction cycle.nnnCONCLUSIONnAlloSCT is the most potent postremission therapy for AML and is particularly active for patients 45 to 59 years of age and/or those with high-risk cytogenetics.
Leukemia | 2015
Elias K. Mai; Uta Bertsch; Jan Dürig; Christina Kunz; Mathias Haenel; Igor Wolfgang Blau; Markus Munder; Anna Jauch; B. Schurich; Thomas Hielscher; Maximilian Merz; B. Huegle-Doerr; Anja Seckinger; Dirk Hose; Jens Hillengass; Marc-Steffen Raab; Kai Neben; Hans-Walter Lindemann; M. Zeis; Christian Gerecke; Ingo G.H. Schmidt-Wolf; Katja Weisel; C Scheid; Hans Salwender; H. Goldschmidt
We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (⩾VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to ⩾VGPR rates (37.0 versus 34.3%, P=0.001). The rates of progressive disease (PD) were 0.4% (VCD) versus 4.8% (PAd; P=0.003). In the PAd arm, 11 of 12 patients with PD had either renal impairment (creatinine ⩾2u2009mg/dl) at diagnosis or the cytogenetic abnormality gain 1q21, whereas no PD was observed in these subgroups in the VCD arm. Leukocytopenia/neutropenia (⩾3°) occurred more frequently in the VCD arm (35.2% versus 11.3%, P<0.001). Neuropathy rates (⩾2°) were higher in the PAd group (14.9 versus 8.4%, P=0.03). Serious adverse events, both overall and those related to thromboembolic events, were higher in the PAd group (32.7 versus 24.0%, P=0.04 and 2.8 versus 0.4%, P=0.04). Stem cell collection was not impeded by VCD. VCD is as effective as PAd in terms of achieving ⩾VGPR rates with fewer PD and has a favorable toxicity profile. Therefore, VCD is preferable to PAd as induction therapy.
Leukemia | 2018
H. Goldschmidt; Henk M. Lokhorst; Elias K. Mai; B. van der Holt; I. W. Blau; Sonja Zweegman; Katja Weisel; Edo Vellenga; Michael Pfreundschuh; M. J. Kersten; C Scheid; Sandra Croockewit; Reinier Raymakers; Dirk Hose; Anna Potamianou; Anna Jauch; Jens Hillengass; Marian Stevens-Kroef; Marc S. Raab; Annemiek Broijl; Hans-Walter Lindemann; G. Bos; P Brossart; M. van Marwijk Kooy; Paula F. Ypma; Ulrich Duehrsen; Ron Schaafsma; Uta Bertsch; Thomas Hielscher; Le Jarari
The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18–65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95% confidence interval (95% CI) of 0.65–0.89, P=0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR=0.89, 95% CI: 0.74–1.08, P=0.24). The incidence of SPM were similar between the two arms (7% each, P=0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size ⩾10%) and renal impairment at baseline (serum creatinine >2u2009mgu2009dl−1) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR=1.02, P=0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.
Bone Marrow Transplantation | 2000
Michael Fuchs; C Scheid; Armin Schulz; Volker Diehl; Dietmar Söhngen
Trimethoprim/sulfamethoxazole prophylaxis impairs function of mobilised autologous peripheral blood stem cells
Bone Marrow Transplantation | 2017
C Scheid; L.C. de Wreede; A. van Biezen; Christian Koenecke; Gudrun Göhring; Liisa Volin; J Maertens; J Finke; Jakob Passweg; Dietrich W. Beelen; J.J. Cornelissen; Maija Itälä-Remes; P Chevallier; Nigel H. Russell; Eefke Petersen; Noel Milpied; C. Richard Espiga; Andy Peniket; Jorge Sierra; Ghulam J. Mufti; Charles Crawley; Joan Hendrik Veelken; Per Ljungman; J.Y. Cahn; Emilio Paolo Alessandrino; T.J.M. de Witte; M. Robin; N Kröger
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P<0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P<0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.
Blood | 2005
H. Goldschmidt; Pieter Sonneveld; [No Value] Breitkreuz; B. van der Holt; A Benner; Rmy Barge; Hans-Juergen Salwender; G. Bos; A. Glasmacher; Reinier Raymakers; C Scheid; P. C. Huijgens; R Naumann; Mhj van Oers; A Hanel; Edo Vellenga; P. Wijermans; A. D. Ho; Phm Westveer; G. Verhoef; U Mazitschek; Hm Lokhorst
Blood | 2005
H. Goldschmidt; Pieter Sonneveld; [No Value] Breitkreuz; B. van der Holt; A Benner; Rmy Barge; Hans-Juergen Salwender; G. Bos; A. Glasmacher; Reinier Raymakers; C Scheid; P. C. Huijgens; R Naumann; Mhj van Oers; A Hanel; Edo Vellenga; P. Wijermans; A. D. Ho; Phm Westveer; G. Verhoef; U Mazitschek; Hm Lokhorst